A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Advanced Bone and Soft Tissue Sarcoma

NCT04900766 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

31

Enrollment

INDUSTRY

Sponsor class

Stopped The sponsor has adjusted its R\&D strategy.

Conditions

Unresectable or Metastatic Bone and Soft Tissue Sarcoma

Interventions

DRUG: Mitoxantrone Hydrochloride Liposome Injection

Sponsor

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.